Summit Therapeutics PLC Sponsored ADR Stock News

Summit Therapeutics Inc. (SMMT) is a U.S.-based biopharmaceutical company. It focuses on developing innovative medicines for cancer treatment.

LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors  ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

The image featured for this article is © mezzotint / Shutterstock.com Latest Podcast Episode Eric Bleeker of The AI Investor Podcast catches up with 7investing CEO Simon Erickson 40 min Live News & Earnings • • 0 Updates Stock Market Live September 16: Good TikTok News Boosts Oracle, and the Whole S&P 500 (VOO) More Content Joey Frenette | Sep 16, 2025 Why I'd Buy GRNY Over the SPY Omor Ibne Eh...

LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the headline and body of the release. The Portnoy Law Firm has commenced an investigation into Summit Therapeutics Inc. concerning alleged securities fraud. The corrected release follows.

Investors can contact the law firm at no cost to learn more about recovering their losses

A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.

Summit Therapeutics (NASDAQ:SMMT ) WCLC Update Conference Call September 08, 2025 08:00 AM Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West - Vice President of Clinical Development Manmeet Soni - COO, CFO & Director Urte Gayko - Chief Regulatory, Quality & Pharmacovigilance Officer Robert Duggan - Co-CEO & Executive Chairman Conference Call Participants Y...

Summit Therapeutics PLC (NASDAQ:SMMT) shares dropped sharply on Monday following the release of mixed results from its Phase III HARMONi trial of ivonescimab, a potential lung cancer therapy. The stock fell 23.4% to about $20 in the early afternoon.